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ABSTRACT 
TOBACCO ENHANCES BACTERIAL-INDUCED PERIODONTAL BONE 
LOSS IN MICE 
Mina Iskander 
July 30, 2020 
Background: Tobacco smoking is the leading environmental risk factor for periodontal 
diseases. Delineation of the mechanisms underlying tobacco-induced or exacerbated 
periodontitis is hampered by the lack of an appropriate and reliable animal model.  
Hypothesis: We hypothesized that Porphyromonas-gingivalis-infected, cigarette smoke-
exposed mice would represent reproducible models of acute (ligature model) and chronic 
(oral gavage model) tobacco-enhanced periodontitis that reflect multiple aspects of the 
disease noted in human smokers. 
Methods: In a chronic oral gavage disease model, Balb/c mice (6-8 weeks, 4 groups of n 
= 6 per group) were exposed to smoke produced by a Teague-10 smoking machine from 
1R6F research cigarettes (20 cigarettes per day over 3 hours; mean carbon monoxide 
(CO), 150 ppm; mean particulate exposure, 4.9 mg/m3) or exposed to ambient air, over 
68 days. The mice were repeatedly orally inoculated with Streptococcus gordonii and 
Porphyromonas gingivalis or sham inoculated. At euthanasia, the IgM and IgG response 
to infection; systemic inflammatory mediators; specific local gingival inflammatory indices 
(IL-1β, MMP-8, MMP-9, CD14and CD45);  as well as alveolar bone  loss were assessed. 
vii 
In an acute ligature-induced disease model, Balb/c mice (6-8 weeks, 4 groups of n = 7 per 
group) were exposed to smoke (20 cigarettes per day over 3 hours; mean CO, 200 ppm; 
mean particulate exposure, 9.8 mg/m3) or exposed to ambient air,  over 14 days. The mice 
were repeatedly orally inoculated with P. gingivalis or sham inoculated. At euthanasia, IgM 
and IgG response to infection, alveolar bone loss was assessed. Plans to assess local 
and systemic inflammatory indices were curtailed by the Covid-19 outbreak. 
Results: In a chronic model of periodontitis, tobacco smoke exposure enhanced bacteria-
induced bone loss (p< 0.01). Systemic innate immune suppression was also apparent, as 
indicated by reduced levels of systemic CCL2, CXCL1, MIP-1b,GM-CSF,IL-13, and IL-10 
(all p< 0.05), while local expression of MMP-8 was augmented in infected mice (p< 0.05). 
However, tobacco smoke exposure did not influence murine mass, IgM or IgG ,or the 
mRNA signal of inflammatory mediator’s in murine gingiva. 
In the acute model of periodontitis, tobacco smoke exposure, again, enhanced bacteria-
induced bone loss (p< 0.01). Body mass differentials were also influenced by smoke 
exposure (p<0.001). However, no significant differences between groups were noted in 
the IgM and IgG responses. 
Conclusions: Tobacco-enhanced periodontitis, as assessed by alveolar bone resorption, 
in both acute and chronic murine models. Such models will facilitate multiple studies that 
can provide mechanistic insights into increased susceptibility to periodontal diseases in 
smokers.  
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
I. Smoking 
1.1 Smoking prevalence and ill-health: 
Tobacco smoking is a primary preventable driver of morbidity and mortality 
globally accounting for 7 million deaths per annum, including the 480,000 fatalities 
associated with passive smoking [1]. In 2018, the prevalence of smoking in the 
U.S. population remains significant, with the number adult cigarette smokers 
estimated at > 34 million adults [2] despite campaigns to minimize or eliminate 
consumption. According to the World Health Organization (W.H.O.), there were 
around 1.3 billion smokers worldwide in 2003, primarily residing in middle-and low-
income countries, a number that is expected to rise to 1.7 billion by the end of 2020 
[3]. U.S. smoking prevalence is highest among in middle-aged individuals (45-64 
years) at 18.0%, is 17.6% in adults of 25-44 years, 13.1% in young adults (18-24 
years), and 8.8% in the elderly (65 years or older) [4]. The W.H.O. suggests 
tobacco use is responsible for the annual deaths of 6 million people worldwide, a 
number projected to rise to 7 million in 2020 and to >8 million by 2030, assuming 
unabated smoking rates [5]. 
Smoking imposes a heavy economic burden, particularly in North America and 
Europe, where the tobacco epidemic is most advanced [6] estimated to be 
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approximately 0.5 trillion dollars annually all over the world[5]. In 2010, smoking 
was estimated to account for 8.7% of the aggregated annual healthcare spending 
in U.S. Approximately two-thirds of this cost was met through Medicaid, Medicare 
or other governmental programs [7]. In the United States the percent attributable 
fraction of deaths due to smoking in U.S. adults in 2014 was highest in Kentucky 
(22.1%) followed by Arkansas (21.5%), Nevada (21.3%), Tennessee (21.1%), 
West Virginia (20.6%), Oklahoma (20.2%) and Missouri (20.1%) [8]. 
About half of all smokers suffer from serious smoking related diseases [9]. 
Smoking is the major driver of at least 30% of all cancer deaths and is associated 
with 80% of early deaths from cardiovascular disease and chronic obstructive 
pulmonary diseases [10]. Furthermore, smokers are more susceptible than 
nonsmokers to premalignant lesions, systemic lupus erythematosus, 
hypertension, osteoporosis, diabetes, Crohn’s disease, impotence and destructive 
periodontal diseases [11-13]. 
The most common product smoked is cigarettes but also smoking can include 
electronic cigarettes, water pipes, pipes, cigar and cigarillos [14]. Indeed, more 
than 7000 constituents that are toxic to human health are contained in cigarettes 
and at least 69 are carcinogenic. Some of these constituents are naturally found 
in tobacco (e.g., nicotine), some are added during the manufacturing process (e.g., 
ammonia), but most are generated during the burning process (e.g., acrolein) [15, 
16]. 
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1.2  Smoking and infectious diseases: 
Smoking, either active or secondhand, increases susceptibility to a multitude 
of infectious, including tuberculosis [17], nasopharyngeal and respiratory tract 
infections [18], surgical infections [19], bacterial meningitis [20] and, of particular 
importance here, periodontal diseases [21, 22]. Whereas the evidence to correlate 
the harmful consequences of smoking to infectious diseases is clear, the 
underlying mechanisms of predisposition require elucidation [23]. To summarize, 
tobacco smoking could enhance the risk of bacterial infection through three 
general mechanisms: (a) tobacco-induced host structural and physiological 
changes, and / or (b) enhancement of bacterial virulence, and/ or (c) immune 
dysregulation [12]. 
The structural changes induced by tobacco smoke may be dependent on the 
specific tissue. For example, cerebral vessels dilate upon exposure to smoke [24], 
whereas, peripheral arterial vessels constrict [25]. In the gingival and periodontal 
tissues, smoking leads to suppression of the gingival inflammation characterized 
by a compromised bleeding response to plaque associated with angiogenesis 
impairment rather than any acute vasoactive activity [26]. 
With respect to bacterial virulence, it was recently reported that cigarette smoke 
promotes the pathogenicity of variant species, such as Staphylococcus aureus 
[27], Haemophilus influenzae, Streptococcus pneumoniae [28]and, the subject of 
this research project, Porphyromonas gingivalis [22, 29]. While there is still much 
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research performed on this topic, smoking alters the phenotypic and genotypic 
virulence traits, to be addressed later. 
Tobacco smoking affects both innate and adaptive immunity [30]. The innate 
immunity is significantly deregulated by smoke. For example, cigarette smoke 
negatively influences differentiation, viability and function, such as phagocytic 
capacity, of neutrophils and monocytes, aiding pathogenic colonization and 
infection [31, 32]. Tobacco smoke components also negatively regulates the 
maturation and function of dendritic cells, the primary antigen presenting cells 
required for adaptive immune function against pathogens [30, 33]. Indeed, T cell 
proliferation,  antigen-mediated T-cell signaling and B cell responsiveness are all 
compromised by smoke exposure. function is compromised in smokers [34, 35]. 
There is a decrease in CD4 lymphocytes and increase in CD8 lymphocytes CD8 
in heavy smokers [36]. Because CD4 lymphocytes stimulate B-cell proliferation 
and differentiation as well as synthesis of immunoglobulins, serum levels of 
Immunoglobulin G (IgG), an important anti-microbial antibody, in smokers are 
reduced when compared to non-smokers [35]. 
1.3 Smoking and the microbiome: 
In recent years, the effects of smoking on the oral microbiome were extensively 
studied and the oral microbiome shift occurs in response to this environmental 
stress [37-39]. However, after periodontal nonsurgical treatment and smoking 
cessation, a vast number of health associated species recolonize in the 
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subgingival microbiome while a significantly lower abundance and prevalence of 
putative periodontal pathogens exists [40]. Smoking develops commensal-poor, 
pathogen-rich microbial ecosystem, allowing pathogen to proliferate  even in 
clinically healthy individuals that closely resemble disease-associated 
communities [41, 42]. Smoking also may promote an anaerobic oral environment 
and a bacterial community with reduced capacity of xenobiotic degradation [37]. 
As mentioned early different infectious diseases are associated with smoking, we 
will focus on periodontal diseases.
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II. Periodontal diseases
2.1 Periodontal disease classification: 
Periodontal diseases include a wide variety of chronic inflammatory conditions 
of the bone, ligament (the connective tissue collagen fibers that anchor a tooth to 
alveolar bone) and soft tissues supporting the teeth and/or the gingiva. Periodontal 
diseases begin with localized inflammation of the gingiva, or gingivitis, 
characterized by reversible redness, swelling, and bleeding [43]. This inflammatory 
response is induced by dental plaque, a complex bacterial biofilm attached to the 
teeth and gingival surface. Further, periodontal disease initiation and progression 
is thought to be associated with dysbiotic ecological changes in the oral 
microbiome composition that occurs due to fluctuations in available nutrients 
including tissue breakdown products, interspecies microbial interactions and 
immune system subversion [44]. Host-derived proteinases are a key factor among 
the multifaceted aspects of an overall inflammatory response, particularly matrix 
metalloproteinases and related destructive enzymes which are thought to be 
upregulated, activated, and involved in soft and hard tissue destruction. Among 
other consequences, such proteases lead to loss of periodontium fibers helping 
the bacterial biofilm to migrate along the root surface [45]. The classification 
periodontal disease subtypes depend on severity of the disease (e.g., periodontal 
pocket depth magnitude, clinical attachment loss and alveolar bone loss at the 
affected site) and the geographical context (the number of affected teeth) [46]. 
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2.2  Periodontal disease prevalence: 
The high prevalence of periodontitis reported in adolescents, adults and older 
people makes it a dominant public health concern [47]. It is considered the sixth 
most common human disease [48]. Globally >500 million people suffer from severe 
periodontal disease, while total tooth loss has been reported in > 270 million people 
[49]. However, in USA, periodontitis has been reported to affect almost half of 
population aged over 30 years, representing over 60 million people [50]. 
Periodontitis-associated expenses comprise a significant part of the annual global 
economic burden over $400 billion for oral diseases [51].  
2.3  Systemic disease and periodontal disease association: 
 
A consistent body of evidence supports a negative association between 
periodontal diseases and systemic diseases, such as pulmonary infections and 
chronic obstructive pulmonary disease (COPD) [52-54], poor glycemic control and 
diabetes [55, 56], cardiovascular diseases and stroke [57, 58], rheumatoid arthritis 
[59-62],  poor pregnancy outcome [63] And specific cancers. As an example, 
negative associations between periodontal disease pancreatic, esophageal, 
gastric and head and neck cancer have been reported  [64-68]. Interestingly, each 
millimeter of alveolar bone loss, a common measure of periodontal disease 
severity, has been estimated to increase the risk of tongue cancer > 5.23 times 
[65]. 
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2.4  Periodontal disease prevention and treatment modalities: 
Good oral hygiene, which includes, regular tooth brushing and flossing, is 
crucial in preventing periodontal diseases [69]. Since smoking is a, or perhaps the, 
major risk factor for destructive forms of periodontal disease [26], smoking 
cessation can prevent a considerable proportion of periodontitis cases [70]. 
Indeed, the gingival bleeding response, suppressed in cigarette users [71], 
recovers rapidly following smoking cessation, indicating a recovery of the innate 
immune response to plaque bacteria [26]. Although the role of diet in dental caries 
is more significant compared to periodontal disease, poor diet can, nevertheless, 
negatively affect periodontal tissue homeostasis leading to disease progression 
[72]. For example, vitamin C scavenges excessive ROS, this nutrient is considered 
an important dietary oxidant in the periodontium [73]. Vitamin C also plays a key 
role in preventing and slows down the progression of periodontal disease by 
inducing the differentiation of periodontal ligament progenitor cells [74]. insufficient 
vitamin C intake increases periodontal disease risk in a dose-related manner [75]. 
The universal approach to treating periodontal disease is the instrumental 
debridement of dental plaque, sometimes accompanied by an antibiotic regimen. 
However, in case of severe subgingival pockets, surgical intervention can be 
necessary [76-78]. While mechanical debridement has been successfully 
implanted in the treatment of periodontal diseases, this technique has many 
drawbacks, for instance patient response is not ideally, universally  and the 
outcome is multifactorial dependent [79]. Deep subgingival pockets may not be 
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completely accessed by scaling devices, mechanical debriding might also be 
inefficient against all periodontal pathogens, as well as other negative impacts, 
particularly dentin hypersensitivity and teeth loss, reduce the efficiency of 
mechanical treatment approaches [80]. Consequently, in conjunction with 
mechanical debridement, antimicrobial therapy has been suggested to inhibit 
pathogenic bacterial colonization and enhance clinical results [81, 82]. Considering 
the benefits of conjunctional localized or systemic antibiotics to the mechanical 
approach, these strategies reveal non-specific activity and affect beneficial 
organisms living in the oral cavity. In addition, there are many other potential 
threats including the growth of resistant bacteria, possible allergic reactions and 
development of opportunistic fungal infections, suggesting careful consideration 
[83]. Indeed, various non-surgical and surgical options are available to treat 
periodontitis. However, no periodontal treatment option has shown superiority over 
another option [84]. 
2.5 The etiology of periodontal diseases: 
The onset and development of periodontal diseases are promoted by several 
factors, including the oral microbiome, the immune system, oral hygiene, systemic 
health, genetics and environmental risk factors, such diet, stress and – the focus 
of this work – tobacco use. Traditionally, two major hypotheses have been 
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considered. The non-specific plaque theory posited that specific bacteria did not 
play a role in the development of periodontitis. Rather, the combined bacterial 
insult was considered the primary etiological factor [85]. The specific plaque 
theory, on the other hand, posited that there are specific microbial organisms 
correlated with the development of periodontitis [85].  In the latter years of the 20th 
century, this developed into what is known as “red complex theory” which stated 
that a group of three bacterial species, Treponema denticola, Tannerella forsythia 
and Porphyromonas gingivalis, are most frequently associated with disease and 
so, treatment and prevention was aimed at their eradication [86]. However, this 
theory was based on assessments of bacterial species that were defined a priori. 
In other words, red complex theory is not a genuine reflection of the oral 
microbiome, which contains multiple uncultivable species and, more importantly, 
potential pathogens unrecognized at the time. In either case, the molecular probes 
that have been employed were highly selective. 
The current paradigm, based on modern, total microbiome analyses in 
periodontal disease is based on the polymicrobial synergy and dysbiosis model, 
where periodontitis results from dysbiosis of the microbiome [87]. A diverse 
microbiota colonizes the gingival crevice where compatible organisms assemble 
into heterotypic communities. Normally, these communities are in balance with the 
host. The community’s microbial components can vary over time, from site to site 
and from one individual to another. Theoretically, colonization even at low levels 
by a keystone pathogen, such as P. gingivalis, can negatively influence host 
defense mechanisms and enhance the virulence of the entire community [88]. 
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Such microbial dysbiosis is associated with a disruption of tissue homeostasis and 
ultimately leads to periodontal tissue destruction. 
III. 3. Smoking and periodontal disease 
3.1 Risk Factors: 
Non-modifiable risk factors 
Genetics is key to the noted variations in predisposition to periodontal diseases 
[46] and may explain approximately half the population variance in periodontitis 
susceptibility [89]. Genetic variations contributing to functional defects in 
neutrophils and in genes involved in cytokine production are of particular 
importance [90-92]. For instance, the intrafamilial occurrence of Papillon-Lefèvre 
syndrome (PLS), which is a rare autosomal recessive disorder, is associated with 
onset of periodontitis at childhood and early loss of both deciduous and permanent 
teeth. This syndrome caused by mutation in the cathepsin C gene [93, 94]. 
Prepubertal periodontitis in some families could represent partly penetrant  PLS 
[95]. Another example, gene polymorphism of IL-1 has been associated with 
about four-fold increase in IL-1 protein levels in sever periodontitis patients [96]. 
IL-1 is a potent stimulators of bone resorption, and as hyperproduction of this 
cytokines following infection by periodontal pathogens is believed to be one of the 
mechanism of periodontal tissue destruction [97]. 
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Different racial and ethnic groups frequently exhibit great variations in the 
outcome of periodontal diseases. Among the three largest race-ethnicity groups in 
the United States, adult blacks show the highest prevalence of periodontitis and 
the most periodontal tissue loss, followed by Mexican Americans, whereas whites 
show the lowest prevalence of disease and tissue loss [98]. 
Periodontal disease is regularly reported to be more prevalent or more severe 
in men than in women at compatible ages signifying a possible sex/gender 
entanglement in the disease pathogenesis [99-101]. Men exhibit poorer oral 
hygiene and report fewer visits to the dentist than do women. However, when 
correcting of oral hygiene, socioeconomic status, visits to the dentist and age, 
being male is still associated with more severe disease when either attachment 
loss or bone height is used as a measure of periodontal disease[102, 103]. 
Advancing age is another major non-modifiable risk factor [104], with clinical 
attachment loss significantly higher in patients aged 60-69 years compared to 
those in the 40-50 age bracket. [105]. 
Modifiable risk factors 
Poor oral hygiene is associated with periodontal disease, and absence of 
sufficient tooth brushing and other oral hygiene measures may promote bacterial 
deposition and dental plaque buildup on teeth surface that can pave the way for 
inflammatory changes in periodontal tissue [46, 106]. 
Diabetes and periodontitis are complex chronic diseases, related by a close 
and bidirectional association. The risk of periodontitis in diabetic patients is 
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increased up to three times relative to healthy individuals. Moreover, the degree of 
glycemic control is essential in evaluating the risk since the risk for periodontitis 
increased with poor glycemic control [55, 107]. Periodontal disease is considered 
to be one of the six major complications of diabetes and the majority of evidence 
demonstrates a direct relationship between diabetes mellitus and periodontal 
disease [108].  Adult patients with type 2 diabetes or type 1 diabetic patients at all 
ages have more severe periodontal disease than age-matched healthy individuals 
[109-111]. 
It is also apparent that stress reduces salivary flow secretion which, in turn, can 
enhances plaque development [112]. A positive association was observed 
between stress scores, clinical attachment loss and tooth exfoliation [113]. Further, 
academic stress has been associated with poor oral hygiene and gingival 
inflammation, including elevated gingival crevicular levels of  IL-1 [112]. 
Depression may be an additional risk factor for periodontal disease. Various 
clinical studies imply a causal correlation between depression and periodontitis 
[114, 115]. Moreover, periodontal disease may contribute to the onset of 
depression through psychosocial effects (e.g. shame, isolation, embarrassment, 
loneliness) of poor oral hygiene and halitosis, frequent characteristics of patients 
with periodontal disease [115].  
Marijuana, which is used widely for medical and recreational purposes in the 
United States, is a major emerging risk factor for chronic periodontitis. Multiple 
human studies showed increased alveolar bone loss in people using cannabis. 
Data from the National Health and Nutrition Examination Survey (2011-2012) verify 
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that frequent recreational cannabis use is associated with an increase in both 
pocket depth and clinical attachment loss, and higher chances of severe 
periodontitis [116]. Also, a recent meta-analysis demonstrated that cannabis use 
is associated with higher prevalence of periodontitis [117]. 
Cigarette smoking is perhaps the most significant environmental risk factors for 
periodontitis. Smoking alone may account for most cases of periodontitis in 
developed nations [26]. Smokers exhibits earlier disease onset [118], elevated 
rates of diseases progression [119], increased severity and prevalence of the 
disease [118, 120], and less favorable response to treatment [121], compared to 
non-smokers. Further, studies suggest that smoking has a strong dose-related 
influence on periodontal disease [122]. Clinical evidence shows increased gingival 
recession and greater periodontal ligament attachment loss and also deeper 
periodontal pocket depth formation and fewer teeth in smokers than non-smokers 
[21, 123, 124]. Compared to nonsmokers, young adult smokers aged 19 to 30 
years have a higher prevalence and severity of periodontitis when controlled for 
plaque levels [125]. Nicotine, a major component of tobacco smoke, has been 
reported to contribute to degradation of periodontal collagen, and other key 
architectural proteins, by increasing expression and activity of matrix 
metalloproteinases (MMPs), and associated periodontal ligament detachment 
[126, 127]. Multiple studies have also indicated that nicotine and one of its major 
metabolites, cotinine, adversely affect human periodontal fibroblasts proliferation, 
attachment and chemotactic responsive in a dose-related manner [128, 129]. 
Acrolein, another harmful component of smoke may be an impactful player in 
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periodontal tissue destruction, producing a dose-related cytotoxic effect on human 
gingival fibroblasts, with complete inhibition of proliferation and attachment 
apparent at high concentrations [130]. In the inflamed area of periodontium in 
chronic periodontitis patients, a significant decrease in the number of vessels and 
a significant reduction in the intensity of the vascular reaction was observed in 
smokers versus nonsmokers [131].  These data suggest that smoking may induce 
angiogenesis suppression, providing a possible explanation of reduced gingival 
bleeding on probing (a common characteristics of periodontitis) in smokers 
compared to nonsmokers among periodontitis patients [26]. 
In sum, tobacco smokers are not only more susceptible to periodontal disease, 
but they are also more likely to develop a severe form of infection which is often 
times refractory to treatment [12, 21]. Moreover, the clinical parameters of 
periodontitis (redness, edema and gingival bleeding) don't correlate to the disease 
level in tobacco smokers, who consistently manifest a reduced inflammatory 
response [21, 132]. 
3.2 Quantification of smoking-related periodontitis risk: 
Worldwide, there are approximately 1.1 billion smokers, most of whom live in 
low- and middle-income countries, where the morbidity and mortality burden of 
smoking is higher [133]. In a study in New York State, involving 1361 people aged 
25 to74 years, smokers where at greater risk of experiencing severe bone loss 
than nonsmokers, with odds ratios ranging from 3.25 (95% CI: 2.33 to 4.54) to 7.28 
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(95% CI: 5.09 to 10.31) for light and heavy smokers, respectively [103]. Data 
derived from the Third National Health and Nutrition Examination Survey, 
conducted in 1988 to 1994 on 12,329 adults conclude that smoking may be 
responsible for more than half of periodontitis cases among adults in the United 
States [70]. A recent meta-analysis, pooled adjusted risk ratio estimate that 
smoking increases the risk of periodontitis by 85% with risk ratio1.85 (95% CI1: 5 
to 2.2) [134]. All of these findings and others [135, 136] provide extensive evidence 
that smoking may be the major preventable risk factor for periodontitis. 
3.3 Potential mechanisms of tobacco-enhanced periodontal disease: 
Smoking compromises multiple and varied aspects of the innate and adaptive 
immune responses [13, 137]. Neutrophils are the primary leukocytes involved in 
host defense against bacterial invasion [91]. However, both in vivo and in vitro 
studies show that smoking impairs chemotaxis and phagocytosis in neutrophils in 
periodontal tissues [138, 139], leading to defective bacterial clearance and 
increased pathogen colonization. 
Cigarette smoke exposure also causes T cell unresponsiveness. Nicotine 
impairs antigen mediated signal transduction in lymphocytes and induces a state 
of T cell anergy [140]. Nicotine inhibits the antibody forming cell responses through 
impairment of antigen mediated signaling in T cells by suppressing the intracellular 
calcium responses [36]. Besides affecting T cell responses, nicotine modulates the 
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production of inflammatory cytokines by alveolar macrophages [141]. Higher levels 
of TNF- have been reported in smoker’s gingival cervical fluid (GCF) compared 
with non-smokers [142, 143]. Also, elevation in interleukin (IL)-1, IL-6 and IL-8 
levels in gingival cervical fluids was observed in periodontally diseased subjects 
as compared to healthy subjects [144]. In addition, higher concentration of matrix 
metalloproteinase (MMP)-8 [145] and MMP-9 in GCF, key host-derived destructive 
proteolytic enzymes, has been described [145, 146].  Smokers have a vast 
increase in ratio between the receptor activator of nuclear factor-κβ ligand 
(RANKL) and its inhibitor osteoprotegerin (OPG) [147]. Osteoclast which 
considered the key player in tissue degradation, differentiated from 
macrophage/monocyte precursor under the regulation of RANKL. Osteoclastic 
activity is promoted by TNF-α and IL-1 especially in inflammatory osteolysis states 
such as those seen in periodontitis [148]. Furthermore, smoking has been found 
to be inversely associated with levels of serum IgG antibodies specific to certain 
periodontal pathogens [35, 149], including P. gingivalis [150, 151]. Additionally, 
smoke can inhibit the reactive oxygen species in phagocytic innate cells, which are 
important in bacterial killing [152]. 
Taken all together, the neutrophils impairment, T-cell anergy, elevated TNF-
α, higher destructive enzymes in GCF, inhibited immunoglobulins and ROS, and 
higher ratio of RANKL/OPG ultimately leads to upregulation of bone resorption and 
increase severity of periodontitis. 
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Nicotine and periodontitis 
Smokers oral tissues are exposed to high concentrations of nicotine which may 
have a negative impact on local cell population. The nicotine concentration in GCF 
has been reported to be almost 300 times that of plasma  in smokers  [153]. In 
smokers, nicotine binds to the root surface [154] and in vitro experiments indicate 
that it causes alteration of the fibroblast attachment [155] and integrin expression 
[156] as well as reduceing collagen production and enhancing collagenase 
synthesis [157]. Smokers root surfaces show reduced attachment of PDL 
fibroblasts compared to those of non-smokers [158]. Higher amounts of the 
proinflammatory cytokines IL-6 and IL-1 are produced from cultured fibroblasts 
[159] and keratinocytes [160] , in contrast to the innate suppression widely reported 
in innate immune cells. 
Moreover, there is strong evidence of a synergistic effect of nicotine and 
bacterial lipopolysaccharide [159, 161]. Animal studies have clarified some of the 
negative impacts on bone healing following local nicotine exposure [162] being 
positively correlated to delayed revascularization [163] and inhibition of specific 
cytokines [164]. During hard and soft tissue wound recovery, smoking has been 
found to inhibit revascularization [163, 165], which is a crucial component of 
periodontal regeneration, dental implant success and plastic surgery procedures. 
Tobacco smoke toxicity 
The smoke generated from tobacco burning represents a dynamic, complex 
and reactive mixture of over 5000 chemicals [63, 166], including carbon monoxide, 
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carbon dioxide, tar, ammonia, acrolein, formaldehyde, acetone, benzopyrenes, 
hydroxyquinone, cadmium, nitrogen oxides, and the primary neuroactive 
compound, nicotine [167]. Nicotine has been shown to be able to alter specific 
cellular functions. For example, nicotine exposure to human fibroblasts derived 
from periodontium affects cell growth, as well as attachment [168]. Both gingival 
fibroblasts (GFs) and periodontal ligament fibroblasts (PDLFs) exhibit lower cell 
viability with greater nicotine and cigarette smoke extract  (CSE) concentrations 
[169], while. PDLFs are more sensitive to nicotine compared to GFs [170] and 
hence, nicotine induce cytotoxicity on PDLFs by inhibiting cell growth, proliferation 
and protein synthesis [168, 171]. 
 
Dysbiosis 
There is a significant difference in the microbial profiles of smokers and 
nonsmokers. The microbial communities are more highly diverse and commensal-
poor in smokers, versus non-smokers [172, 173]. However, in another study, the 
overall oral microbiome composition of former smokers did not differ significantly 
from that of never smokers; indicating that smoking-related changes to the oral 
microbiome are not permanent [37]. Several important periodontal pathogens, 
including Treponema denticola, Fusobacterium nucleatum and P. gingivalis, are 
over-represented in cigarette users, relative to non-smokers [174], while  
commensal species, such as Streptococcus species, may be in higher abundance 
in non-smokers compared to smokers [38]. Several mechanisms were proposed 
to clarify how smoking may alter microbial ecology, including significantly low 
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oxygen tension within the periodontal pockets in smokers, which might favor the 
growth of anaerobic periodontal pathogens even in shallow pockets [175]. This 
was supported by the clinical findings that smoking creates a favorable habitat for 
bacteria, such as P. gingivalis at shallow sites (≤5 mm) [138], increasing the acidity 
of saliva [176], influencing bacterial adherence to mucosal surfaces [177] and 
impairing host immunity [178]. 
4. Porphyromonas gingivalis
4.1  Porphyromonas gingivalis characteristics: 
P. gingivalis is a Gram-negative, rod-shaped, asaccharolytic bacterium that is 
a secondary colonizer of subgingival plaque, forming black colonies on blood agar 
due to its potent hemin-acquisition capacity [179]. The primary site of P. gingivalis 
in the human oral cavity is the subgingival sulcus. P. gingivalis depends on the 
fermentation of amino acids for the production of energy and, thus, for its existence 
in deep periodontal pockets [180]. P. gingivalis possesses a variety of virulence 
factors that are important in colonization and persistence in the oral cavity [181]. 
The onset and progression of periodontal tissue damage is a complex process 
involving plaque deposition and dysbiosis, secretion of bacterial products and the 
inflammatory response of the host. 
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4.2 P. gingivalis and periodontal disease: 
The oral cavity houses the second most diverse microbial community in the 
body containing over 700 species of bacteria, only a small number of which have 
been associated with disease [181]. Of these, P. gingivalis is heavily implicated in 
periodontal disease development and progression. Undesirable shifts in 
periodontal biofilm communities, such as pathogenic P. gingivalis growth, drive the 
dysregulation of host homeostasis.  P. gingivalis is the archetypal periodontal 
pathogen and, as such, will be used herein to induce periodontitis in mice. Indeed,  
P. gingivalis has been considered as a keystone pathogen of periodontitis, at least 
in mice [182].  P. gingivalis can be commonly isolated from plaque biofilms in 
periodontal disease patients but is rarely isolated from healthy individuals [183]. P. 
gingivalis has also been strongly associated with the extent of gingival pocket 
depth.  There is an estimated 10-fold rise in the number of P. gingivalis cells for 
every 1- millimeter increase in pocket depth at human diseased sites [184]. 
An animal study [185] supports the evidence that P. gingivalis, even at low 
abundance, is capable of inducing significant alteration to host commensal 
microbiota in a way that supports its own viability while promoting pathogenesis of 
the disease.  In this study, specific pathogen free mice infected with  P. gingivalis 
exhibited significant bone loss, which is a major characteristic of periodontal 
disease. In contrast, germ free mice infected with P. gingivalis mono-infection 
showed no significant bone loss indicating that P. gingivalis cannot induce bone 
loss by itself. 
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4.3 P. gingivalis virulence factors: 
Capsule 
The polysaccharide-rich external capsule of P. gingivalis serves a role in 
microbial adhesion to the teeth or mucosal surface. The capsule also provides 
protection from phagocytic clearance by neutrophils [186]. P. gingivalis shows at 
least six capsular antigen serotypes, K1-K6 [187]. Studies using mouse infection 
models showed that encapsulated P. gingivalis strains are much more virulent than 
non-capsulated. Non-encapsulated strains are mostly responsible for non-
invasive, localized abscesses, whereas encapsulated strains are responsible for 
destructive lesions and systemic spreading. The non-encapsulated strains also 
suffer increased phagocytosis and are quickly removed by dendritic cells and 
macrophages [187]. Further, a decreased level of pro-inflammatory cytokines (IL-
1,IL-6, and IL-8) was detected when human gingival fibroblast was infected with 
a P. gingivalis mutant which lacks a capsule as opposed to a wild-type strain which 
produces a capsule [188]. Therefore, the capsule appears to be a key activator of 
the inflammatory response. 
Gingipains 
The RgpA, RgpB (arginine specific) and Kgp (Lysine specific) gingipains are a 
primary virulence factor of P. gingivalis [189] [190]. Gingipains are detected at high 
concentrations in GCF collected from deep pockets that are infected with P. 
gingivalis [191]. Their major roles in periodontitis pathogenicity are related to their 
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ability to manipulate host immune defense and degrade host proteins. The broad 
specificity of gingipains means that they target multiple mammalian structural 
proteins (e.g., collagens and fibronectin, and laminin) and immune effector proteins 
(e.g., cytokines, antibodies, complement components, antimicrobial peptides and 
leukocytes surface receptors) [192, 193]. In addition, RgpB activity is essential for 
assembly of fimbriae, another major virulence factor of P. gingivalis [194]. 
Treatment with a specific gingipain inhibitor strongly attenuates P. gingivalis 
virulence [195]. Importantly, gingipains are an attractive therapeutic target as 
immunization with purified gingipains or DNA vaccines protects against P. 
gingivalis infection in mice [196] . 
 
Fimbriae: 
Fimbriae are protein-like, filamentous appendages that protrude from the cell 
surface of bacteria. They play a vital role in virulence by promoting bacterial 
attachment to the host cell and other bacteria. P. gingivalis possesses both major 
fimbriae, largely comprised of the FimA protein [197], and minor fimbriae, largely 
comprised of Mfa1 protein [198].  
P. gingivalis major fimbriae are crucial virulence to colonization, facilitating 
adhesion to several host proteins such as laminin, fibronectin, collagen and 
salivary proteins [199] and to other bacteria, such as oral streptococci species 
[197]. Fimbriae also help in the invasion of oral epithelial cells and gingival 
fibroblasts [200] and induce the expression several pro-inflammatory cytokines 
such as IL-1,IL-6 and TNF-, thus priming the immune system [201]. 
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The minor fimbriae are key in adhesion to the primary periodontal colonizer, S. 
gordonii  through specific interaction between Mfal and the SspB protein expressed 
on the surface of S. gordonii  [202]. Unlike FimA [203], Mfa1 is highly inflammatory 
and induces IL-6,IL-1, TNF- in mouse peritoneal macrophages and is 
associated with alveolar bone loss in various mouse models of periodontitis [204]. 
Lipopolysaccharide 
Another virulence component of P. gingivalis is the lipopolysaccharide (LPS) 
that makes up outer leaflet of the bacterial outer membrane. LPS is a hybrid 
molecule of lipids and carbohydrates that is abundant in, and adds structure 
integrity to, the outer membrane [205, 206]. LPS plays a crucial role in initiation of 
inflammation, triggering macrophage [207], neutrophils [208] and gingival 
fibroblasts [209] to secret inflammatory cytokine on interaction with cognizant 
innate receptor molecules. P. gingivalis LPS, as well as LPS from other Gram-
negative species, induce the production of cytokines and other inflammatory 
mediators, through LPS-Toll-like receptor-4 (TLR-4)- nuclear factor-κB (NF-κB) 
axis [210]. P. gingivalis LPS has also been implicated in increasing the risk of 
important systemic conditions, such as atherosclerosis via the induction of foam 
cell formation in murine macrophages [211]. P. gingivalis LPS can directly activate 
osteoclasts and causes the release of the cytokines IL-1 and TNF- from 
macrophages, monocytes, and fibroblasts [212]. These compounds are potent 
local mediators of bone resorption and, moreover, can inhibit collagen synthesis 
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by osteoblasts and induce the production of host metalloproteases that destroy  
bone and connective tissue [148]. 
4.4 Smoking and P. gingivalis prevalence: 
A correlation between cigarette smoking and subgingival infection with 
periodontal pathogens has been long established. P. gingivalis is found in 
significantly higher numbers in smokers compared to non-smokers and the 
infection is more persistent [213]. In a sample of 272 adults with periodontal 
disease, it was confirmed a significant difference in proportions of red-complex 
bacteria including P. gingivalis, in current smokers compared to those in former 
smokers and never smokers [214]. Another self-reported data on 1426 subjects 
aged 25 to 74, showed a  significantly higher proportions of smokers harbored 
Aggregatibacter actinomycetemcomitans, Tanmirella forsythia and P. gingivalis 
than were non-smokers [215]. Eggert et al. showed that smoking extends a 
favorable habitat for bacteria such as P. gingivalis to shallow sites (≤5 mm) [216]. 
Also, based on the results of qPCR, 40 smokers showed significantly higher 
amount of P. gingivalis than 40 nonsmokers in chronic periodontitis with equal 
probing depths [217]. From all these finding we conclude that the evidence for 
tobacco smoke increasing susceptibility to P. gingivalis infection and increasing 
the P. gingivalis infectious load is particularly strong. 
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4.5 Smoking and alterations to P. gingivalis virulence: 
Nicotine and its major metabolite, cotinine, do not influence the growth of P. 
gingivalis even at concentrations of  400µg/mL, which are higher than their 
physiological levels in saliva and GCF [218]; and indicative of profound resistance 
t these antimicrobial alkaloids [219]. Similarly, P. gingivalis growth showed to be 
unaffected by whole cigarette smoke extract (CSE) exposure at concentrations of 
0.5, 2, and 4 µg/mL nicotine equivalents [29, 220] . While P. gingivalis growth is 
not directly influenced by smoke, some changes in the virulence factors of bacteria 
are observed. For example; CSE influences the cell-bound Kgp and RgP gingipain 
production in a strain-specific manner (suppression in P. gingivalis ATCC 33277 
but augmentation in P. gingivalis W83) [221]; CSE exposure decreased the 
proinflammatory capacity (TNF-a, IL-6) of P. gingivalis biofilms [22]; CSE exposure 
altered multiple gene expression profiles (such as DNA repair and oxidative stress-
related  genes) [29]; CSE up-regulated the expression of FimA, suppressed the 
production of capsular polysaccharides, altered the proinflammatory response to 
CSE-exposed bacteria, and induced the expression of the outer membrane 
virulence factors, RagA and RagB [29, 201]. However, many of these effects were 
reversed when bacteria exposed to CSE were sub-cultured in fresh medium 
without CSE [29]. Therefore, smoking may profoundly influence the P. gingivalis 
phenotype and its subsequent interactions with the immune system. 
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5. Animal models of periodontitis:
To gain better insight into the mechanisms underlying periodontal diseases, 
animal models that replicate key aspects of this human disease set will be useful. 
Despite the limitation of utilizing animal models, its often less severe than those 
encountering during in vitro experiments, in which cells are examined on plastic 
surface with limited number if cells types presented. Moreover, animal models 
often allow more definitive analysis of course and effect relationships than human 
clinical studies [222]. Animal periodontal disease models that have been employed 
include mice, rats, dogs and non-human primates [223]. Animal models generate 
substantial and relevant data on the interactions between soft and hard tissue, 
especially during inflammation, and hence periodontal inflammatory models, can 
be simulated and tested in animals. Another major advantage is that the potential 
mechanisms of systemic inflammation and its impact on periodontal healing 
processes can be studied in vivo using genetically produced transgenic and 
knockout animals [224]. A crucial aspect in animal models is the opportunity to 
explore complex interactions between bacteria and host which cannot be carried 
out under artificial laboratory conditions using single cell populations. 
 In contrast, animal models such as rodents differ substantially from humans in 
that their incisors lack a root structure and grow continuously throughout life, with 
only the front of the incisors having enamel and provide minute amount of gingival 
tissue. Therefore, relatively large numbers of animals per group are needed. Also, 
it is important to keep in mind these anatomical differences and similarities when 
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considering which aspects of oral anatomy and health can be appropriately 
modeled in periodontitis [225]. 
However, tobacco-specific disease mechanisms have received relatively little 
attention in in vivo systems [26]. Characteristics of smoking-enhanced periodontitis 
in humans include a tobacco-specific microbial dysbiosis [226], dysregulated 
cytokine networks [30], amended neutrophil and other innate cell function [152], a 
protease-antiprotease imbalance [13], and an altered adaptive immune response 
[178], most notably reflected in a profound suppression of IgG production [227]. All 
of these phenomena culminate in increased soft and hard tissue destruction [228]. 
An ideal animal model, which does not exist, would encompass all of these 
disease-related traits. 
5.1 Mouse models of periodontitis: 
A model was developed in which mice were orally infected for studying the 
effect of host response on P. gingivalis-induced alveolar bone loss [229, 230]. It 
has been hypothesized that P. gingivalis initiates experimental periodontitis, at 
least in part, by alternating the endogenous subgingival biofilm to acquire 
increased virulence properties [231]. On one hand, this model may not reproduce 
all aspects of human periodontitis as the use of a single is not represenetive of the 
complex microflora that comprises the dental plaque biofilm [232]. On the other 
hand, the use of P. gingivalis in murine models provides many advantages such 
as allowing the study of natural history of periodontal tissue destruction, 
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comparison of the level of virulence of P. gingivalis and other oral pathogens 
including ), a controlled environmental conditions, and estimations of efficacy of 
periodontal therapeutic strategies [234].  
In an alternative periodontitis model, a silk ligature is be placed around the 
molar teeth in the gingival sulcus which enhances biofilm accumulation in addition 
to disturbing the gingival epithelium,which results in enahnced osteoclastogensis 
and bone loss [223]. A major benefit of the ligature-induced periodontitis model is 
that disease can be initiated in a matter of days with a predictable sequence of 
events culminating in alveolar bone loss [235]. However, in small animals such as 
mice, the possibility for mechanical trauma by the ligatures, might contribute to 
bone loss cannot be excluded [236].  
 
5.2 Rat models of periodontitis: 
 
Rats periodontal anatomy in the molar region shares some similarities with that 
of humans. So, they are often used in models of experimental periodontitis. Also, 
rats are easy to handle and can be obtained with different genomes and microbial 
status. Periodontitis can be induced by placing a bacterial plaque-retentive silk or 
cotton ligature in the gingival sulcus around the molar teeth [61]. In addition, 
injection of P. gingivalis can induce alveolar bone loss in rats [62]. Previous studies 
have shown the influence of smoking on the periodontal disease induced in rats. 
It has been found that cigarettes smoking potentiated bone loss in ligature‐induced 
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periodontitis in rats [237]. Also, smoke exposure cessation seems to reverse its 
impact on mandibular bone [238]. 
 In sum, rodents include some unique features for evaluating microbial and host 
response to complement primate and human periodontal studies. Rodents have in 
each quadrant three molars  and one incisor only [223]. 
One of periodontal disease aspects is bacterial colonization of the tooth surface 
and connective tissue invasion. A challenge with many rodent models of 
periodontal diseases is that the bacteria employed to induce the infection 
development only infect the oral cavity transiently, because rodents are not natural 
host for many human bacteria [230]. The presentation of human bacterial strains 
into the oral cavity and consequent effects on periodontal tissue has been studied 
in varies rodent models  [239, 240]. Different human bacterial strains were used in 
animal models such as Treponema denticola [241], A. actinomycetemcomitans 
[242], Tannerella forsythia  [243] and P. gingivalis [229, 244]. In many cases, the 
oral infection by human bacteria is transient. Nevertheless, T. denticola has been 
detected 71 days after inoculation in mice [241]and P. gingivalis has been detected 
at up to 11 weeks [245]; 45% of rats exposed to P. gingivalis and 80% exposed to 
T. forsythia or T. denticola were found to harbor these bacteria after 4-6 weeks 
[246]. 
Another hallmark of periodontal diseases is the alveolar bone resorption [44]. 
Significant bone loss can be measured histologically, by macroscopic analysis or 
by micro-computed tomography. Alveolar bone resorption often assessed around 
the maxillary molars since bone resorption in lower molars is slower due to wider 
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buccolingual dimensions and thicker cortical alveolar bone [230]. In many reports 
bone resorption was detectable 6 weeks after the final inoculation [229, 247], 
although other studies have shown a detectable alveolar bone loss as early as 3 
weeks after first infection or 2 weeks after the final bacterial challenge  [248]. Both 
mice and rats are susceptible to alveolar bone loss however there are differences 
in the susceptibility to experimental periodontal disease among various strains. 
BALB/c, DBA/2J and C3H/HEN are more susceptible than C57/B16, SJL/J and 
C3H/HeJ  [249]. These differences are correlated to genetic variation in the strains 
affecting components of the immune response. For example, the point mutation 
on Toll-like receptor 4 (TLR4) in C3H/HeJ mice or differences in adaptive immunity 
[250]. Normal variation in the genetics, in addition to modification by genetic 
engineering, in mice creates a potentially valuable option for developing a cause-
and-effect association with both aspects of the host response and periodontal 
disease. 
Bacterial inoculation-induced immune response in mice might be comparable 
to that associated with periodontitis in humans. Downregulation of the innate 
immune response promotes host-microbe homeostasis and highly orchestrated 
expression of certain host defense cytokines and mediators is associated with 
healthy periodontal tissues [251]. Virulence factors produced by some oral 
pathogens might inhibit neutrophils transmigration into the periodontium; cytotoxic 
to recruited neutrophils; or promote leukocytic longevity [91]. For example, P. 
gingivalis secrets a serine phosphatase enzyme (SerB), may play an important 
role in preventing granulocyte recruitment to the periodontal tissues as, in a rat 
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model [245]. SerB also responsible for inhibition of interluiken-8 secretion from 
epithelial cells infected with P. gingivalis, so in the absence of SerB more 
neutrophils are recruited into the gingival tissue [245]. Also, in rats ligature induce 
periodontitis model, administration of nicotine enhanced alveolar bone loss 
concomitant with a reduced pro- and anti- acute inflammatory cytokine response 
to LPS (TNF, transforming growth factor- β, IL- 10) [252]. Chronic exposure of rats 
to nicotine inhibits antibody-forming cell responses and this immunosuppression 
appears to be the result of impairment of antigen mediated T cell signaling [253, 
254]. 
A variety of proteolytic enzymes are involved in the normal homeostatic 
remodeling of the periodontium including natural turnover and pathological 
degradation of the alveolar bone. In periodontal disease, degradation of ligament 
and alveolar bone can be excessive and lead to progressive break down of the 
periodontal supportive tissue [255]. Matrix metalloproteinase 8 (MMP-8), a 
collagenolytic enzyme responsible for  pathological degradation of type I collagen, 
the predominant type of collagen in periodontium. The role of MMP-8 was 
investigated in mouse model study, where MMP-8 knockout mice and wild type 
mice were orally infected by P. gingivalis to induce periodontitis [256]. A 
histological analysis showed that bone loss was significantly higher  in the P. 
gingivalis-infected Mmp-8−/−group compared to the P. gingivalis-infected WT 
group. The study concluded that MMP-8 plays a protective role in alveolar bone 
loss during periodontal infection, possibly by inactivating pro-inflammatory 
cytokines. 
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5.3 Canine models of periodontitis: 
Dogs provide a suitable model for testing naturally occurring gingivitis and 
periodontitis [257]. The genera isolated from the oral cavities of dogs were typical 
of those found in human dental plaque included Actinomyces, Porphyromonas, 
Fusobacterium, Neisseria, and Streptococcus [258]. Also, periodontal disease in 
dogs is highly correlated with aging and thus the etiopathology is closely related to 
humans [259]. A study to investigate deleterious effect of nicotine on the canine 
periodontium, oral or systemic nicotine administration to dogs has been associated 
with increased blood flow to the anterior gingiva, relative to untreated controls 
[260]. Another study noted that applying a solution of tobacco smoke to gingiva of 
dogs might suppress crevicular innate cell migration in neutrophils isolated from 
both inflamed and healthy sites [261]. 
As a limitation, some major difference exists between humans and dogs  as the 
lack of lateral movements, presence of open contacts between teeth and no 
occlusal contacts for all premolars [262]. Other important differences between 
dogs and humans are lack off gingival sulcus and cervical fluids, and a different 
composition of periodontal plaque and calculus [263]. 
5.4 Non-human primate models of periodontitis 
Monkeys have the advantage of probably being phylogenetically similar to 
humans. Most of species have same dental formula as human and have naturally 
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occurring dental plaque, calculus, oral microbial pathogens (e.g., P. gingivalis), 
and periodontal disease [223, 262]. Microbiologically, in Macaca fascicularis 
(cynomolgus monkeys), the composition of the plaque is Gram positive rods and 
cocci for supragingival plaque and anaerobic Gram negative rods for subgingival 
plaque [264, 265]. The inflammatory response to periodontal disease is quite 
similar to that found in humans wherein connective tissues are infiltrated by plasma 
cells, lymphocytes and neutrophils [262]. To study periodontitis and promote 
plaque formation, sutures or orthodontic elastics are commonly placed around 
selected molars until pocket formation is confirmed by probing [266]. Another 
alternative modification to use primates for periodontitis, 
Cynomolgus monkeys with no previously detectable P. gingivalis have been 
treated with the bacteria. About 5 months later, infection by P. gingivalis was 
confirmed and plaque formation leading to bone loss was observed [267]. 
The disadvantages of non-human primate models are difficulty in obtaining a 
large number of animals to perform adequate statistical analysis of the results , 
high cost to provide special husbandry requirements, animals are prone to 
systemic infections and diseases. Moreover, ethical considerations and 
regulations must be fulfilled in order to prevent any trafficking of protected species 
[268]. Collectively, these limitations make non-human primates a less practical 
model for periodontal disease. 
In conclusion, relevant similarities in gingival and tooth anatomy between 
humans and mice, availability of mouse smoke-exposure chambers , existing 
literature on rodent models of periodontal disease and the need to prioritize the 
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use of lower vertebrates, all collectively suggested mice as the most appropriate 
model to experimentally advance our knowledge of smoking-related periodontal 
disease mechanisms. 
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Hypothesis and Aims 
We hypothesized that Porphyromonas-gingivalis-infected, cigarette smoke-
exposed mice would represent  reproducible models of acute (ligature model) and 
chronic (oral gavage model) tobacco-enhanced periodontitis that reflect multiple 
aspects of the disease noted in human smokers. 
Aims 
We set out to examine if tobacco-smoke exposure, in two murine bacterial-
induced periodontitis models, was associated with: 
• A suppressed local and / or systemic innate response,
• A suppressed anti-bacterial IgG response.
• Enhanced alveolar bone loss.
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CHAPTER 2: MATERIALS AND METHODS 
Carboxymethyl cellulose (CMC) was purchased from Sigma Aldrich 
Corporation (St. Louis MO, USA). Phosphate Buffered Saline (PBS) was 
purchased from Life Technologies (Grand Island NY, USA). Streptococcus 
gordonii (S . gordonii) DL-1 and P. gingivalis 33277 were purchased from the 
American Type Culture Collection (Manassas, VA) and maintained as frozen 
stocks. BD BBL Brain-heart infusion broth, Mitis Salivarius agar and Difco 
bacteriological agar were purchased from Difco Laboratories Inc.  Potassium 
tellurite was from SIGMA (St. Louis, MO). Gifu anaerobic medium was from (GAM; 
Nissui Pharmaceutical, Tokyo, Japan). Oral gavage needles were obtained from 
Cadence Science Inc. Cranston, RI). Puritan swabs were from (25-800 D 50) 
(Puritan Medical Products Co., Guilford, ME). Gentamicin solution was purchased 
from SIGMA (St. Louis, MO). Sheep blood was purchased from Lampire Biological 
Laboratories (Pipersville, PA). Midori Green was from Bulldog-Bio (Portsmouth, 
NH). Methylene Blue and Eosin were obtained from Ricca Chemical Company (TX, 
USA). RNeasy mini kit and RLT buffer were from QIAGEN (Hilden, Germany). Taq 
2X Master Mix (M0270) was from NEW ENGLAND BIOLABS (MA, USA). qScript 
XLT reverse transcriptase was from (Quantabio, USA). Real-Time PCR Master 
Mix and mouse primers were from TaqMan Thermo Fisher Scientific, USA. BD 
Microtainer blood collection tubes were from Becton Dickenson. Trizol™ Reagent 
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was from Thermo Fisher Scientific, USA). Mouse/Rat Cotinine ELISA was from 
CALBIOTECH (CA, USA). Genomic DNA Purification kits were from Promega 
(Madison, WI). 16s PCR primers were purchased from Bio-Synthesis Inc. 
(Lewisville, TX, USA). Anti- mouse IgM-HRP antibody was purchased from 
BETHYL Laboratories (Montgomery, TX) and horse anti-mouse IgG-HRP antibody 
from Cell Signaling Technology (Danvers, MA). Mouse Cytokine / Chemokine 
Magnetic Bead Panel was purchased from (MiliporeSigma, USA). Immunocal was 
purchased from StatLab Medical Products (McKinney TX, USA). Research 
cigarettes (1R6F) were purchased from University of Kentucky. Membrane filters 
were from Pall life sciences (Port Washington, NY). 6–0 black non absorbable 
surgical silk (SURGICAL SPECIALTIES LOOK Co, USA). DEXDOMITOR was 
from Zoetis, USA. Ketamine was from Henry Schein, Inc Co. Puralube Vet 
Ointment was from (1-800-PetMeds, Delray Beach, FL). Heat Pad from K & H Pet 
Products. Ligature holders were from University of North Carolina [269] and the 
modified design was from University of Louisville Oral Health and Rehabilitation 
Department. CO2 was provided by Welders Supply Co. (Louisville, KY).  Nikon 
SMZ 800 dissecting microscope (40X, Nikon Instruments Inc., Melville,35 NY, 
USA) fitted with a Boeckeler VIA-170K video image marker measurement system 
was from Boeckeler Instruments Inc, Tucson, AZ, USA. 
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Mice 
White BALB/c mice, 6-8 weeks old, females, were purchased from Jackson 
laboratory. All the experimental procedures were performed in accordance with the 
Guidelines of the Institutional Animal Care and Use Committee of University of 
Louisville, as described in the Federal Guidelines for the Care and Use of 
Laboratory Animals. Animals were housed and maintained at the University of 
Louisville, School of Dentistry in a room maintained by the Research Resources 
Facility. Cages for animal housing were changed weekly, unlimited food and water 
provided throughout the duration of the experiment with a 12-hour light/dark cycle 
and controlled temperature and humidity. 
Smoking machine and cigarettes : 
Teague TE-10 whole body smoke inhalation exposure system was utilized to 
conduct the mouse exposures (Teague Enterprises; Davis, CA) [270]. 1R6F 
research cigarettes were from University of Kentucky (8.58mg of tar/cigarette; 
0.721mg nicotine/cigarette; additives). 
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Smoking Machine Teague Enterprises TE-10C : 
Figure 1: The smoking machine Teague  Enterprises TE-10C 
The TE-10c is a microprocessor-controlled cigarette smoking machine that 
produces smoke from research cigarettes. From one to ten cigarettes can be 
smoked at a time. The machine’s applications include use with animal and cell 
culture exposure systems and serial animal exposure chambers. The machine is 
composed of four sections: cabinet, cigarette handling, chimney, and ash 
collection tray. 
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We performed two different in vivo experiments. Firstly, a modified Baker Model 
was utilized where an S. gordonii infection was added along with an increase in 
the number of P. gingivalis infections with smoke/no smoke exposure for 68 days. 
Secondly, we utilized a ligature model with P. gingivalis infection with smoke/no 
smoke exposure for 14 days.   
 
Growth of Bacterial Strains  
 
S. gordonii was cultured anaerobically for 16 hr. at 37°C without shaking in 
brain-heart infusion supplemented with 1% yeast extract. P. gingivalis was cultured 
in Gifu medium under anaerobic conditions (80% N2, 10% H2, and 10% CO2) at 
37oC. Growth was monitored by tracking optical density at a wavelength of 600 
nm. The oral infection of mice by S. gordonii and/or P. gingivalis was performed as 
showed in Figure 2 timeline strategy. 
 
Animal Exposure to Smoke 
Female white BALB/C mice were placed into either a cigarette smoke exposure 
(CSE) chamber or a sham exposure chamber (ambient filtered room air) of the 
Teague TE-10C exposure apparatus chamber for a period of 3 hours daily. 
Cigarettes were smoked using the standard Federal Trade Commission method: 
a two second, 35 cm3 puff, once a minute for a total of 9 minutes. One pack of 20 
research cigarettes was used per day. In order to monitor the daily cigarette smoke 
levels, carbon monoxide (CO) concentration and total suspended particulates 
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(TSPs) were measured twice daily.  The level of CO within each exposure chamber 
was determined using a carbon monoxide detector with a digital readout in parts 
per million. TSPs were recorded twice daily by drawing a known volume of air 
during a 5-minute period from the exposure chamber via a sampling port and 
collecting TSPs on a piece of filter paper. The difference in weight pre- and post-
sampling was divided by the volume of air that was drawn from the chamber during 
an interval of five minutes while sampling the exposure chamber. After the smoke 
exposure, animals were returned to their home cages. Food and water were 
changed daily in smoke cages. 
For the Baker model, mice were exposed to ambient air or cigarette smoke, 20 
cigarettes per day over 3 hours, 7 days per week for 68 days. CO levels during the 
exposure were kept at an average of 150 ppm. Mean TSP throughout the 
experiment was 4.9 mg/m3. For the ligature model, mice were exposed to ambient 
air or cigarette smoke 20 cigarettes per day over 3 hours, 7 days per week for 14 
days. CO levels during the exposure were kept at an average of 200 ppm. TSP 
mean was 9.8 mg/m3. 
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Modified Baker Model: 
The Baker Model of bacterially initiated periodontal disease [229] describes a 
method of orally infecting mice with P. gingivalis leading to alveolar bone loss. It is 
aimed at allowing mice to naturally develop periodontitis over a period of time 
similar to development of periodontitis in humans. It closely mimics the chronic 
nature of periodontitis. Alveolar bone loss is detected after 10 weeks. 
In our modified Baker Model, mice were repeatedly orally inoculated with S. 
gordonii and P. gingivalis (109 colony-forming units (CFU) in 100 ml 2% 
carboxymethylcellulose) or sham inoculated (vehicle alone) as shown in Figure 2. 
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Timeline strategy for Baker model bacterial inoculation 
Figure 2: Bacterial inoculation timeline for smoke- or ambient air-exposed mice. 
Days of inoculation are represented by green arrows for S. gordonii  (109 CFU) 
and red arrows for  P. gingivalis (109 CFU). 
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Day 0 
There were 4 groups: 
1. Group 1  (Sham infection / no smoking exposure),
2. Group 2 (Bacteria infection / no smoking exposure),
3. Group 3 (Sham infection / smoking exposure),
4. Group 4 (Bacteria infection / smoking exposure).
46 
Mice group assignment for Baker model 
Figure 3: Baker model  group assignment: Female Balb/c mice (6-8 weeks) 
distributed in four groups (n=6). Group 1, sham infection and no smoking exposure; 
Group 2, bacterial infection and no smoking exposure; Group 3, sham infection 
and smoking exposure and Group 4, bacterial infection and smoking exposure. 
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Day 0 through Day 4 
Mice acclimated to the surrounding environment; no smoking exposure or 
infection was done at this time.  
Day 5 
Mice were exposed to ambient air or cigarette smoke (20 cigarettes per day 
over 3 hours), continued daily until euthanasia. 
Day 12 though Day 18 
Mice were infected orally with S. gordonii in PBS and carrier CMC at a 
concentration of 109 CFU/mouse in 100 l PBS and 2% CMC. A gavage needle 
was used to infect mice locally in the buccal vestibule around the molar area. Sham 
infected mice received 2% CMC in 100 μl PBS with 2% CMC. The mice were 
infected with S. gordonii for a total of four times. The infection was done every 
other day.  
Day 20 through Day 55 
Mice were infected orally with P. gingivalis in PBS and carrier CMC at a 
concentration of 109 CFU/mouse in 100 l PBS and 2% CMC. A gavage needle 
was used to infect mice locally in the buccal vestibule around the molar area. Sham 
infected mice received 2% CMC in 100 μl PBS. The infection was done every other 
day for six times followed by two subsequent infections every two weeks for a total 
of ten times infection. The sham-infected mice were treated in the same manner 
as the bacterial infected mice except that they received just PBS and CMC. 
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Day 72 
Mice were euthanized 42 days after the last P. gingivalis infection. Inhalation 
of carbon dioxide was used as the standard method to euthanize the mice. The 
flow of carbon dioxide was maintained at (1.5 liters) until at least 1 minute after 
respiratory arrest. The secondary method was decapitation/exsanguination. 
Oral swabs for S. gordonii and P. gingivalis: 
Oral swabs were obtained from all mice by swabbing the buccal vestibule molar 
area of the gingiva using Puritan polyester tipped swabs. This was done to detect 
the presence of S. gordonii in the oral cavity, to assess the effectiveness of S. 
gordonii infection, to monitor the prevalence of S. gordonii in the different treatment 
groups, to detect the presence of P. gingivalis in the oral cavity, to assess the 
effectiveness of P. gingivalis infection and to monitor the prevalence of P. gingivalis 
in the different treatment groups. Oral swabs were collected for S. gordonii 
detection one day after the second infection, one day after the third infection, one 
day after the six rounds of P. gingivalis infection, then every two weeks until the 
final swab at the time of euthanasia. 
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Oral swabs time frame for Baker model. 
Figure 4: Oral swabs time frame for Baker model represented by blue arrows. 
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S. gordonii detection was performed by two methods: 
1. Plate culture:
The periodontal microbiota was sampled by swabbing the buccal vestibule 
around the molars, then streaked directly onto Mitis Salivarius agar plates 
supplemented with 0.1% potassium tellurite solution (1%) for aerobic culture at 
37oC for 1-2 days. 
Plates were examined for appearance of colonies and those with small deep 
dense colonies believed to be more representative of S. gordonii colonies. Entire 
plates scraped into 200 l nuclease free water. 5 µl suspension used in the gftG 
PCR. 
2. . Standard Polymerase Chain Reaction for S. gordonii:
Entire plates scraped into 200 l nuclease free water.  5 l suspension used for 
Standard PCR procedure and run on 2% agarose gel electrophoresis at 120V to 
detect the presence of the amplified glucosyltransferase Gene (gftG) [271]. 
• gftG  primers, Fragment size is 440 (bp);
gftG upstream     5⸍-CTATGCGGATGATGCTAATCAAG-3⸍ 
gftG downstream   5⸍-GGAGTCGCTATAATCTTGTCAGA-3⸍ 
and the cycling conditions: 10min at 95oC, 35 cycles of 15 sec at 95oC, 35 
cycles of 15 sec at 50oC, 35 cycles of 30 sec at 68oC, 5min at 68oC and holding at 
4oC. This assay was done to detect presence of S. gordonii only using a crude 
preparation. No attempt was made for quantification. 
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P. gingivalis detection: 
 Mice were sampled by swabbing the maxillary gingiva using Puritan swabs. 
This was done to detect the presence of P. gingivalis in the oral cavity, to assess 
the effectiveness of infection and to monitor the prevalence and persistence of P. 
gingivalis in the different treatment groups. Oral swabs were collected for P. 
gingivalis detection one day after each infection and then every two weeks after 
last infection. 
P. gingivalis detection was performed by two methods: 
1. Plate culture. 
 The periodontal microbiota was sampled by swabbing the buccal vestibule 
around molars, then the swab tips were submerged into 300l anaerobic balanced 
GAM broth followed by plating onto blood agar plates (100 μl/plate) and CFU were 
enumerated following anaerobic growth for 1 month and examined at 1, 2 and 4 
weeks. P. gingivalis was identified by black pigmented colonies and Gram staining. 
 
2. Standard PCR procedure and 2% agarose gel electrophoresis at 120V to 
detect the presence of  the amplified P. gingivalis 16S Gene [272]. 
• P. gingivalis 16S  primers, Fragment size is 404 (bp); 
P. gingivalis 16S  upstream              5⸍-AGGCAGCTTGCCAT ACTGCG-3⸍ 
P. gingivalis 16S   downstream         5⸍-ACTGTTAGCAACTA CCGATGT-3⸍ 
and the cycling conditions: 30 sec at 95oC, 30 cycles of 15 sec at 95oC, 30 
cycles of 15 sec at 48oC, 30 cycles of 1 min at 68oC, 5min at 68oC and holding at 
4-10oC. 
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Specimen collection and analysis: 
1. Tissue harvest
Gingival tissue of the entire maxilla was excised around the molar area and 
was immersed in RLT buffer (Qiagen). Samples were flash frozen on dry ice then, 
stored at -80ºC. The tissue was disrupted by sonication and RNA prepared using 
RNeasy kit following the manufacturer’s protocol. RNA concentration was 
determined using a NanoDrop nucleic acid quantification instrument (Thermo 
Fisher) and equalized before cDNA preparation using qScript XLT (Quanta bio). 
Real-time quantitative PCR (qPCR) analysis of gingival tissue was performed 
using the TaqMan system to determine cytokine mRNA expression of inflammatory 
markers (IL-1, MMP-8, MMP-9, CD14, CD45) with GAPDH housekeeping gene. 
2. Serum:
Cardiac puncture was used to collect blood from each mouse, which was added 
to gel tubes (BD Microtainer) and allowed to clot at room temperature for 30 
minutes followed by centrifuging according to the protocol.  Sera were aliquoted 
and stored at -80°C for later assessment of systemic inflammatory mediators by 
multiplex ELISA and IgG and IgM. P. gingivalis reactive antibodies were 
quantified by ELISA. 
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Serum P. gingivalis immunoglobulin detection protocol 
Serum was tested for P. gingivalis cognizant IgG and IgM antibodies, as 
determined by ELISA.  Briefly, P. gingivalis was fixed in formalin and washed three 
times in PBS and diluted to an OD600nm of 0.3 and plated in 96 well microtiter plate 
after blocking for 12 hours at 4°C as described [245]. Diluted mouse sera (1:200) 
were reacted with bacteria for 2h at room temperature. After washing, goat anti-
mouse IgM or horse anti-mouse IgG (both conjugated to HRP) (1:1000) were 
added to the plate. After washing 7 times, TMB was applied and incubated for 
5min. The assay reactions were terminated by the addition of 1N H2SO4 and 
analyzed at an OD450nm using a Bio-Rad microplate reader. 
3. Alveolar bone loss evaluation:
Freshly harvested skulls were submerged in tap water and boiled for 8 minutes. 
After de-fleshing gently with micro brushes and running water, the skulls were 
immersed overnight in 3% hydrogen peroxide. The following day, the skulls were 
immersed for 1 min in 1% bleach, washed and air dried. The maxillae were stained 
with 0.5% eosin for 5 min followed by 1% methylene blue for 1 minute. Alveolar 
bone loss was measured using a SMZ 800 dissecting microscope fitted with a VIA-
170K video image marker measurement system. Bone loss was measured at 14 
predetermined points on the maxillary molars of de-fleshed maxillae, determined 
as the distance from the cementoenamel junction (CEJ) to the alveolar bone crest 
(ABC). Bone loss was calculated by subtracting the mean CEJ-ABC distance of 
the control group from the CEJ-ABC distance of each experimental group. 
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Microscopic image of mice maxillary teeth 
Figure 5: Microscopic image of mice maxillary teeth showing the seven sites 
of measurement from the CEJ to ABC (depicted by yellow stars) on the left 
buccal  side after staining with methylene blue for visualization of the CEJ. 
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Ligature model: 
The ligature-induced periodontitis model is another method of modeling 
periodontal disease.  This model has the advantage of being initiated at a known 
time with a predictable sequence of events culminating in alveolar bone loss within 
a few days [235]. In the present study, mice were repeatedly orally inoculated with 
P. gingivalis (109 colony-forming units (CFU) in 100 ml 2% carboxymethylcellulose) 
or sham inoculated (vehicle alone) as in Figure 6. 
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Timeline strategy for ligature model bacterial inoculation 
Figure 6: Ligature placement and bacterial inoculation strategy for smoke- or 
ambient air-exposed mice. Days of inoculation are represented by red arrows 
where P. gingivalis (109 CFU) or sham infections (CMC) were administered orally 
3 times/as shown in the timeline. 
Tobacco smoke exposure 20 cigarettes daily over 3 hours(or sham exposure) 
57 
Day 0 
Upon arrival of mice, mice were randomized and distributed in groups (n=7 per 
group). Mice tails were marked for identification of groups and individual animals. 
Mice weights were recorded every other day till the end of experiment. 
There were 4 groups of mice: 
1. Group 1  (Sham infection / no smoking exposure / Ligature),
2. Group 2 (Bacteria infection / no smoking exposure/ Ligature),
3. Group 3 (Sham infection / smoking exposure/ Ligature),
4. Group 4 (Bacteria infection / smoking exposure / Ligature).
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Mice group assignment for Ligature model 
Figure 7: Ligature model mouse group assignment: female Balb/c mice (8 
weeks) distributed in four groups (n=7). Group 1 ligature, sham infection and no 
smoking exposure, Group 2 ligature, Bacteria infection and no smoking exposure, 
Group 3 ligature, sham infection and smoking exposure and Group 4 ligature, 
Bacteria infection and smoking exposure. 
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All four experimental groups had their right maxillary second molar ligated by 
6–0 black non absorbable surgical silk positioned around the tooth with the ligature 
holder [269] and then tied gently with a lingual side knot to prevent damage to the 
periodontal tissue. The contralateral molar tooth in each mouse was left unligated 
to serve as baseline control for bone height measurements.  
 
Day 0 through Day 3 
Mice acclimated to the surrounding environment. No smoking exposure or 
infection was done at this time. 
Day 3 through Day 7 
Mice were exposed to ambient air or cigarette smoke 20 cigarettes per day 
over 3 hours till the day of euthanasia. 
Day 8 
Mouse groups number 1 and 3 were anesthetized for the placement of the 
ligature around the right maxillary second molar with Ketamine/ Dexmedetomidine. 
Dosing was as follows: 
Ketamine dose is 65 mg/kg. 
Dexmedetomidine dose is 0.65 mg/kg. 
Mice were placed on a heating bed until recovered from anesthesia, and eye 
ointment was applied to protect against eye dryness. Mice were sham infected 
locally around maxillary molars with 100 µl PBS (2% CMC) as described 
previously. Sham infection was repeated on alternate days for three times (Days 
8, 10 and 12). 
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Day 9 
Mouse groups 2 and 4 were anesthetized for the placement of the ligature 
around the right maxillary second molar with the same previously mentioned dose 
followed by oral infection with P. gingivalis (109 CFU/mouse) in 100 l PBS/2% 
CMC. The infection was repeated every other day for three days (Days 9, 11 and 
13). 
Day 15 
Mouse groups number 1 and 3 were euthanized 7 days after the ligature 
placement. Inhalation of carbon dioxide was used as the standard method to 
euthanize the mice. The flow of carbon dioxide was to 1.5 liters per minute. Carbon 
dioxide flow was maintained for at least 1 minute after respiratory arrest. The 
secondary method was decapitation/exsanguination. 
Day 16 
Mouse groups number 2 and 4 were euthanized 7 days after the ligature 
placement. Inhalation of carbon dioxide was used as the standard method to 
euthanize the mice. The flow of carbon dioxide at 1.5 liters per minute was 
maintained for at least 1 minute after respiratory arrest. The secondary method 
was decapitation/exsanguination. 
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Specimen collection: 
1. Tissue harvest
Gingival tissue of the entire maxilla was excised around the molar area and 
immersed in buffer (Trizol 500 l). Samples were stored at -80ºC until used for 
RNA isolation following the manufacturers protocol. Real-time quantitative PCR 
(qPCR) analysis of gingiva is planned to determine cytokine mRNA expression of 
inflammatory markers using TaqMan system. However, this was not possible due 
to lab and core facilities closure associated with the COVID-19 outbreak. 
2. Serum:
Cardiac puncture was used to collect blood from each mouse. Serum was 
stored at 80°C for later assessment. Serum was tested for P. gingivalis exposure 
by analyzing total P. gingivalis cognizant IgG and IgM antibodies, as determined 
by ELISA. Analysis of systemic inflammatory mediators by multiplex ELISA is 
planned. However, this was not possible due to lab and core facilities closure 
associated with the COVID-19 outbreak 
3. Alveolar bone loss evaluation:
Freshly harvested skulls were submerged in deionized water and boiled for 8 
minutes, followed by de-fleshing, and gentle cleaning with micro brushes and 
running water. Skulls were then soaked overnight in 3% hydrogen peroxide before 
being immersed for 1 min in 1% bleach, washed and air dried. The maxillae were 
stained with 0.5% eosin for 5 min followed by 1% methylene blue for 1 minute. 
Alveolar bone loss was measured in millimeters at 14 predetermined points on the 
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maxillary molars of de-fleshed maxillae as the distance from the cementoenamel 
junction (CEJ) to the alveolar bone crest (ABC). 
     Statistical analysis: 
Data were evaluated by ANOVA or t-test, as appropriate, using InStat v3.06 
program (GraphPad, San Diego, CA), unless otherwise described. Significance 
was set at the p < 0.05. 
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CHAPTER 3 RESULTS 
We examined the influence of cigarette smoke exposure on oral health in two 
different murine models of periodontitis. First, 68 days, bacterial-induced, chronic 
disease model was exploited. Second, a 14 day, acute disease model in which 
bacterial-induced bone loss was accelerated by the placement of molar ligatures 
was utilized. 
3.1 Chronic Disease (Baker) Modeling 
As detailed in the Materials and Methods section, mice were randomly 
assigned into 4 groups (6 mice per group): uninfected and sham smoked controls; 
uninfected, smoke-exposed (68 days, 20 cigarettes/day, 3 hrs. per day); mice 
orally inoculated multiple times with S. gordonii then P. gingivalis and sham 
smoked; and mice both infected and smoke-exposed. Mass was assessed at 
baseline (Figure 7) and prior to euthanasia (Figure 8). Weight gain was also 
monitored (Figure 9). The IgM and IgG response to infection (Figures 10 and 11); 
systemic inflammatory mediators (Table 1); specific local gingival inflammatory 
indices, IL-1β (Figure 12), MMP-8 (Figure 13), MMP-9 (Figure 14), CD14 (Figure 
15) and CD45 (Figure 16); as well as alveolar bone loss (Figure 17) were
assessed. 
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Figure 8: Equal murine body mass at baseline in the chronic smoke exposure 
model. 
6-8-week-old, female Balb/c mice were randomly divided into 4 groups (n = 6 / 
group) and weighed prior to induction, or not, of bacterial-induced chronic 
periodontal disease in the presence or absence of mainstream stream smoke. 
Data is presented as mean ± s.d. 
There were no significant differences in baseline mass between groups, as 
determined by ANOVA (p > 0.05). 
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Figure 9: Chronic smoke exposure does not influence murine body mass. 
Balb/c mice were weighed at 68 days following the induction, or not, of 
bacterial-induced chronic periodontal disease in the presence or absence of 
mainstream stream smoke (n = 6 / group). 
Data are presented as mean ± s.d. 
There were no significant differences in murine mass between groups at 
euthanasia, as determined by ANOVA (p > 0.05). 
0
5
1 0
1 5
2 0
2 5
3 0
 M
a
s
s
 (
g
)
S m o k e d  -   -  +   +
B a c te r ia  -   +   -   +
66 
0
2
4
6
8
M
a
s
s
 d
if
fe
r
e
n
c
e
 (
g
)
S m o k e d  -   -  +   +
B a c te r ia  -   +   -   +
Figure 10: Chronic smoke exposure does not influence murine body mass 
differentials. 
Difference of Balb/c mice body mass between base line weight and the weight 
at 68 days following the induction, or not, of bacterial-induced chronic periodontal 
disease in the presence or absence of mainstream stream smoke (n = 6 / group). 
Data are presented as mean ± s.d. 
There were no significant differences in murine mass differentials between groups, 
as determined by ANOVA (p > 0.05). 
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Table 1: Bacterial colonization of the oral cavity of mice in the absence of cigarette 
smoke.  
 
Bacterium 
Detection 
method 
SWAB 
1 
SWAB 
2 
SWAB 
3 
Paper 
Point 
SWAB 
4 
SWAB 
5 
SWAB 
6 
S. gordonii 
PCR + +  - +    + 
Culture + +  + +  + 
P. gingivalis 
PCR           - - + - 
Culture          -     + - - 
 
A positive colonization score for S. gordonii, by PCR, was defined as the 
visualization of 440 bp amplicons in samples isolated from >3 / 6 mice. 
 
A positive colonization score for P. gingivalis, by PCR, was defined as the 
visualization of 405 bp amplicons in samples isolated from >3 / 6 mice. 
 
A positive colonization score for S. gordonii, by culture, was determined by the 
visualization of streptococcal-like colonies on Mitis Salivarius agar plates. 
 
A positive colonization score for P. gingivalis, by culture, was determined by 
the visualization of black pigmented colonies on blood agar plates. 
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Table 2: Bacterial colonization of the oral cavity of mice chronically exposed to 
cigarette smoke. 
Bacterium Detection 
method 
SWAB 
1 
SWAB 
2 
SWAB 
3 
Paper 
Point 
SWAB 
4 
SWAB 
5 
SWAB 
6 
S. gordonii PCR + + - + + 
Culture + + + + + 
P. gingivalis PCR - - - - 
Culture - - - 
A positive colonization score for S. gordonii, by PCR, was determined by the 
visualization of 440 bp amplicons in samples isolated from >3 / 6 mice. 
A positive colonization score for P. gingivalis, by PCR, was determined by the 
visualization of 405 bp amplicons in samples isolated from >3 / 6 mice. 
A positive colonization score for S. gordonii, by culture, was determined by the 
visualization of streptococcal-like colonies on Mitis Salivarius agar plates. 
A positive colonization score for P. gingivalis, by culture, was determined by 
the visualization of black pigmented colonies on blood agar plates. 
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Figure 11: P. gingivalis-cognizant IgM is elevated in infected, chronically smoke- 
exposed mice. 
IgM titers were measured by ELISA post-euthanasia. 
Differences between groups were determined by ANOVA. 
Data are presented as mean ± s.d. values (n = 6 per group). 
*p< 0.05.
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Figure 12: Infection induces a P. gingivalis-cognizant IgG response that is not 
influenced by chronic smoke exposure in mice.  
IgG titers were measured by ELISA post-euthanasia. 
Differences between groups were determined by ANOVA. 
Data are presented as mean ± s.d. values (n = 6 per group). 
***p < 0.001. 
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Table 3: Chronic smoke exposure alters aspects of the systemic immune response 
to P. gingivalis. 
Inflammatory Mediator Bacteria/Sham Smoked Bacteria/Smoke 
Mean (s.d.) [pg/ml] 
CCL2 52(14) 20(22)** 
CCL5 17(7) 17(6) 
CXCL1 133(23) 85(30)** 
CXCL10 499(74) 509(113) 
MIP-1a 73(21) 47(38) 
MIP-1b 104(16) 84(14)* 
G-CSF 375(168) 435(177) 
GM-CSF 35(14) 11(15)** 
IFN-g 6(2) 4(3) 
TNF-a 11(2) 9(1) 
IL-1a 755(163) 689(186) 
IL-5 21(8) 18(10) 
IL-10 21(3) 17(2)* 
IL-13 67(10) 57(5)* 
IL-15 18(29) 17(20) 
IL-17 3(3) 5(4) 
IL-9 198(45) 283(89)* 
Concentrations of inflammatory mediators in mouse serum were measured by 
multiplex ELISA following euthanasia. 
Differences between groups were determined by t-test. 
Data are presented as mean ± s.d. values (n = 6 per group). 
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(IL-12p40, IL-12p70, IL-7, IL-6, IL-4, IL-2, and IL-1b) fell outside the range of the 
standard curve. 
*p < 0.001, ** p < 0.01, respectively.
. 
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Figure 13: Chronic cigarette smoke exposure does not influence IL-β message in 
murine gingiva. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The IL-1β mRNA relative to that of glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was measured post-euthanasia by qPCR in gingival tissues in (A) non-
infected exposed and (B) infected mice. 
Differences between groups were determined by t-test. 
Data are presented as mean ± s.d. values (n = 6 per group). 
p > 0.05. 
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Figure 14: Chronic cigarette smoke augments the MMP-8 signal in bacteria-
infected murine gingiva. 
The MMP-8 mRNA signal, relative to that of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was measured post-euthanasia by qPCR in gingival 
tissues in (A) non-infected exposed and (B) infected mice. 
Differences between groups were determined by t-test. 
Data are presented as mean ± s.d. values (n = 6 per group). 
*p < 0.05.
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Figure 15: Chronic cigarette smoke exposure does not influence the MMP-9 
message in murine gingiva. 
The MMP-9 mRNA signal, relative to that of glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was measured post-euthanasia by qPCR in gingival tissues in (A) non-infected 
and (B) infected mice.  
Differences between groups were determined by t-test. 
Data are presented as mean ± s.d. values (n = 6 per group). 
*p > 0.05.
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Figure 16: Chronic cigarette smoke exposure does not influence CD14 message 
in murine gingiva. 
The CD14 mRNA signal, relative to that of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was measured post-euthanasia by qPCR in gingival 
tissues in (A) non-infected and (B) infected mice.  
 Differences between groups were determined by t-test. 
Data are presented as mean ± s.d. values (n = 6 per group). 
*p > 0.05.
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Figure 17: Chronic cigarette smoke exposure does not influence the CD45 signal 
in murine gingiva. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The CD14 mRNA signal, relative to that of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was measured post-euthanasia by qPCR in gingival 
tissues in (A) non-infected and (B) infected mice.  
 Differences between groups were determined by t-test. 
Data are presented as mean ± s.d. values (n = 6 per group). 
*p > 0.05. 
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Figure 18: Chronic tobacco smoke exposure enhances bacteria-induced alveolar 
bone loss in mice. 
 Alveolar bone loss was determined as the distance from the CEJ to ABC at 14 
predetermined maxillary buccal sites. 
Differences between groups were determined by ANOVA. 
Data are presented as mean ± s.d. values (n = 6 per group). 
* / ** p < 0.05, 0.01, respectively.
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3.2 Acute Disease (Ligature) Modelling 
As detailed in the Materials and Methods section, mice were randomly 
assigned into 4 groups (7 mice per group): Uninfected and sham smoked controls; 
uninfected, smoke-exposed (14days, 20 cigarettes/day, 3 hrs per day); mice orally 
inoculated multiple times with P. gingivalis and sham smoked; and mice both 
infected and smoke-exposed. Mass was assessed at baseline (Figure 18) and 
prior to euthanasia (Figure 19). Weight gain was also monitored (Figure 20) as 
were the IgM and IgG response to infection (Figures 21 and 22). As in the chronic 
disease model, it was planned to monitor systemic inflammatory mediators, and 
specific local gingival inflammatory indices. However, these experiments were 
curtailed by the COVID-19 outbreak. However, alveolar bone loss (Figure 23) was 
assessed. 
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Figure 19: Equal murine body mass at baseline in the acute periodontal disease 
model. 
6-8-week-old, female Balb/c mice were randomly divided into 4 groups (n = 7 / 
group) and weighed prior to induction, or not, of bacterial-induced acute 
periodontal disease in the presence or absence of mainstream stream smoke. 
Data is presented as mean ± s.d. 
There were no significant differences in baseline mass between groups, as 
determined by ANOVA (p > 0.05). 
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Figure 20: Bacterial infection increased murine body mass in smoke-exposed mice 
in an acute model of periodontitis. 
 
 
 
 
 
Balb/c mice were weighed at following the induction, or not, of bacterial-induced 
acute periodontal disease in the presence or absence of mainstream stream 
smoke (n = 7 / group).  
Differences between groups were determined by ANOVA. 
Data are presented as mean ± s.d. 
* p < 0.05. 
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Figure 21: Smoking suppressed body mass differentials in an acute periodontitis 
model in mice. 
Difference of Balb/c mouse body mass between the base line weight and the 
weight at time of euthanasia following the induction, or not, of bacterial-induced 
acute periodontal disease in the presence or absence of mainstream stream 
smoke (n = 7 / group). 
Differences between groups were determined by ANOVA. 
Data are presented as mean ± s.d. 
** / *** p < 0.01, 0.001, respectively. 
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Bacterial colonization of the oral cavity in acute periodontitis model in mice: 
 
Detection of bacterial colonization by culture and PCR in the acute periodontitis 
model was planned. However, this was not possible due to lab and core facilities 
closure associated with the COVID-19 outbreak. 
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Figure 22: Infection induces a P. gingivalis-cognizant IgM response that is not 
influenced by smoke exposure in an acute periodontitis model in mice. 
IgM titers were measured by ELISA post-euthanasia. 
Differences between groups were determined by ANOVA. 
Data are presented as mean ± s.d. values (n = 7 per group). 
* p < 0.05.
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Figure 23: P. gingivalis cognizant-IgG is not influenced by smoke exposure in an 
acute periodontitis model in mice.      
 
 
 
 
IgG titers were measured by ELISA post-euthanasia.  
Differences between groups were determined by ANOVA. 
Data are presented as mean ± s.d. values (n = 7 per group). 
All, p > 0.05. 
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The influence of smoke exposure on the systemic immune response to P. 
gingivalis in an acute model of periodontitis. 
Concentrations of inflammatory mediators in mouse serum were to be measured by 
multiplex ELISA following euthanasia. However, this was not possible due to lab and core 
facilities closures associated with the COVID-19 outbreak. 
The influence of smoke exposure on the gingival immune response to P. gingivalis 
in an acute model of periodontitis. 
Specific local gingival inflammatory mediators were planned to be measured 
post-euthanasia by qPCR in gingival tissue. However, this was not possible due to 
lab and core facilities closure associated with the COVID-19 outbreak. 
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Figure 24: Tobacco smokes enhances bacteria-induced alveolar bone loss in an 
acute model of periodontitis in mice. 
Alveolar bone loss was determined as the distance from the CEJ to ABC at 7 
predetermined buccal sites on contralateral sides of maxilla (ligated and non-ligated 
control sides). 
Differences from the non-ligated and ligation-only control groups were determined by 
ANOVA. 
Data are presented as mean ± s.d. values (n = 7 per group). 
* / **/ *** p < 0.05, 0.01, 0.001 respectively, compared to untreated group.
# / ##/ p < 0.05, 0.01, respectively, compared to compared to ligature only group. 
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CHAPTER 4 DISCUSSION 
Periodontal diseases are highly prevalent, chronic inflammatory diseases of the 
tissue surrounding the teeth that lead to significant oral depilation [273]. Disease 
initiates and progresses when the balance of a complex interplay between the host 
immune response and microorganisms of the dental biofilm – or homeostasis - is 
disrupted. P. gingivalis, a causative agent of periodontal disease, is a Gram-
negative, black pigmented, assacharolytic anaerobic bacteria that facilitates the 
subversion of the host immune response and, as a consequence, is thought to 
promote dysbiotic polymicrobial synergy  [187, 273, 274]. Tobacco smoking is 
considered the strongest modifiable environmental risk factor for periodontitis 
[138]. 
Finding a reliable and reproducible animal model of periodontal disease that 
reproduces all aspects of human disease is unlikely. However, we hypothesized 
that two murine models would reflect at least some of the tobacco-specific facets 
of periodontal disease in humans. Most importantly, enhanced alveolar bone loss. 
Mice are an attractive model due to relevant gingival and tooth anatomy relatively 
low cost, availability of extensive genetic tools, a large existing literature 
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and availability of rodent smoke-exposure chambers. When aligned with the 
prioritization of the use of lower vertebrates, mice appear to be the appropriate 
animal, to explore in the context of smoking-related periodontal disease 
mechanisms. 
There are key aspects of tobacco-enhanced human periodontal disease that 
differ from the disease in non-smokers i) enhanced and persistent infection with P. 
gingivalis and other periodontal pathogens [12, 138]; ii) a suppressed IgG 
response to pathogens [35, 149]; iii) a suppressed local and systemic pro-
inflammatory response [26]; iv) an elevated endogenous protease burden [146]; 
and, most critically, (v) exacerbated oral bone loss [123, 124]. In addition, we were 
cognizant of the reduced body mass apparent in human smokers. Thus, we 
evaluated these human disease traits in acute and, where possible, chronic, 
smoke-exposed disease models. 
Murine mass was equal in all groups at the start of the experimental period in 
both models.  In the acute, but not chronic model, bacterial infection was 
associated with increased body mass in smoke-exposed mice. 
A positive correlation between weight gain and periodontitis risk has been 
established in humans [275]. It is suggested that lipopolysaccharide (LPS) of 
Gram-negative periodontal bacteria could lead to hepatic dyslipidemia and insulin 
resistance [276]. On the other side, smoking is suggested to reduce weight by 
suppressing the appetite and/or increasing energy expenditure in humans [277, 
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278]. Also, cross-sectional studies clarify that body weight is lower in smokers than 
nonsmokers [279]. However, in our study, smoking by itself did not affect body 
mass. 
In the chronic model, persistent colonization with the commensal bacterium, S. 
gordonii, was readily established in both the sham-smoked and smoked groups, 
as determined by both PCR and culture. This is consistent with the literature, 
where multiple reports confirm colonization of Streptococcus species in the oral 
cavity of mice [280-282]. 
Unlike S. gordonii, we could not detect persistent P. gingivalis colonization, 
other than a single positive culture of black-pigmented rods early in the inoculation 
protocol. Therefore, we must think of our model as a series of transient infections 
rather than the established and persistent colonization by P. gingivalis seen in 
humans [230]. This is most likely explained by the fact that mice are not a natural 
host for P. gingivalis [230].The interaction between S. gordonii and P. gingivalis is 
well established [202, 283]. Therefore, we had hypothesized that an initial infection 
with S. gordonii would enhance colonization of P. gingivalis in our chronic model 
of periodontitis. However, while the P. gingivalis infections may have been 
transient, a robust adaptive immune response was nevertheless induced, as 
determined by the IgG response, while, critically, infection-associated differentials 
in alveolar bone loss were apparent, both phenomena to be discussed later. 
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A robust antibody response to P. gingivalis, reflective of colonization, is noted 
in patients with periodontitis [150, 151]. In our study we examined the association 
between smoking and levels of serum IgM and IgG. In the chronic and acute 
disease models, smoking did not influence the P. gingivalis-cognizant IgM or IgG 
titers. The IgM signal in the presence or absence of P. gingivalis infection likely 
reflects the presence of related Bacteroidetes or other bacteria that may share a 
sub-set of antigens with P. gingivalis. 
 
Such findings are in contrast to the situation in humans, where the overall and 
pathogen-specific IgG response is significantly suppressed in smokers compared 
to nonsmokers, both in general and specifically in patients with periodontal disease 
[35, 227, 284]. 
 
Cigarette smoking alters the development and effector function of innate 
immune cells [30]. However, due to prioritization of experimental outcome 
measures, only systemic and local inflammatory profiling was addressed herein. 
 
In the chronic model of periodontitis, we observed that smoke exposure altered 
specific aspects of the systemic immune response to bacterial infection, with 
significantly reduced levels of CCL2, CXCL1, MIP-1b, GM-CSF, IL-13, and IL-10 
noted in serum from smoked-exposed mice relative to non-smoked control 
animals. Interleukin-10 (IL-10) is a potent anti-inflammatory cytokine that can 
contribute to the maintenance of bone mass through inhibition of osteoclastic bone 
92 
resorption and regulation of osteoblastic bone formation [285]. Also, IL-10-deficient 
mice possess hyperinflammation and are highly susceptible to P. gingivalis-
induced periodontitis [286]. In addition, IL-13 prevents osteoclast precursors from 
differentiating into osteoclasts [287]. Moreover, Granulocyte-macrophage colony-
stimulating factor (GM-CSF) inhibits osteoclastogenesis by diverting osteoclast 
precursors to a macrophage lineage [288]. Among the infected groups, our results 
showed significant lower serum levels of GM-CSF, IL-10, and IL-13 in smoked 
mice relative to non-smoked mice in the chronic model of periodontitis. This can 
explain the associated bone loss in smoked mice discussed later in the current 
study. Our findings are consistent with clinical studies. For instance, it has been 
found that decreased salivary IL-10 level was significantly lower in patients with 
chronic periodontitis as compared with healthy controls [289] Also, Zein et al. 
reported that levels of IL-10, IL-13  were significantly lower in plasma of aggressive 
periodontitis patients compared with healthy [290].In addition, serum GM-CSF 
level was reduced insignificantly in chronic periodontitis patients compared to 
healthy control group [291]. 
We also analyzed the effect of smoking on the mRNA signal of the inflammatory 
markers, IL1, MMP-8, MMP-9, CD14 and CD45, in the maxillary gingiva of mice. 
IL-1β is an archetypal proinflammatory mediator, whose upregulation contributes 
to inflammation and the destructive sequelae that are characteristic features of 
periodontal diseases [292]. IL-1 is detected early in any  immune response to 
pathogens [293]. Therefore, elevated IL-1β levels have been suggested as a 
potentially sensitive aid in monitoring clinical disease activity [294]. In the chronic 
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model of periodontitis, tobacco smoke exposure was associated with reduced 
expression of IL-1β in the maxillary gingiva, regardless of infection, although the 
effect showed high variability and did not reach statistical significance. Rawlinson 
et al. (2003) have previously reported that the IL-1β signal is lower in gingival 
crevicular fluid of adult periodontitis smokers vs. nonsmokers [295]. Indeed, a 
recent review by Buduneli and Scott reported that a general suppression of the 
gingival innate immune response is a consistent conclusion of multiple clinical 
studies [26]. 
Matrix metalloproteinases (MMPs) are a group of enzymes that, in concert, are 
able to degrade most, if not all, extracellular matrix proteins and are considered 
key mediators of periodontal disease progression [296]. Indeed, MMP inhibitors, 
in the form of sub-antimicrobial tetracycline antibiotics, represent an important 
therapeutic tool for use in recalcitrant disease cases [297].  During periodontal 
disease, MMPs are secreted by multiple types of inflammatory cells, including 
macrophages and neutrophils [298, 299]. In smokers, higher concentrations of 
MMPs, in particular MMP-8 and MMP-9, have been reported in gingival crevicular 
fluid and periodontium connective tissue [145, 146]. 
In our chronic periodontitis experiments, smoking exposure significantly 
augments MMP-8 message in the infected group. This increase in the MMP-8 
signal is reflective of another key aspect of periodontitis that is seen in human 
smokers. 
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  CD14 is glycosylphosphatidylinositol-anchored receptor [300] expressed 
predominantly on monocytes and macrophages and, at 10-times lower levels, on 
neutrophils [301]. It is known to serve as a co-receptor for several Toll-like 
Receptors (TLRs) both at the cell surface and in the endosomal compartment. 
CD14, as a co-receptor with TLR4, facilitates cellular responses to low doses of 
bacterial lipopolysaccharide and activation of innate immunity [209, 302, 303]. 
CD45 is, a leukocyte-specific protein tyrosine phosphatase, an abundant cell 
surface protein on lymphocytes [304]. CD45 isoforms are present on all nucleated 
hematopoietic cells and appear to play an important role in the immune cell 
response to stimuli [305]. CD45 causes increase in cytokine production and T-cell 
proliferation [306]. As CD14 and CD45 are, present on the surface of particular 
leukocytes and their expression levels are considered, on this occasion, to act as 
surrogate markers for monocyte and pan-leukocytes infiltration, respectively, into 
the periodontal tissues In the chronic periodontitis model, smoking does not affect 
the expression of CD14 mRNA or CD45 expression in murine gingiva. This is 
consistent with previous studies. For instance, Chen et al. has reported that CD 14 
expression in alveolar macrophages did not differ in smokers versus nonsmokers 
[307]. In addition, smoking did not increase the level of CD 45 in healthy or 
periodontitis gingiva [308]. This can be explained by the masking effect of smoking 
on inflammatory cells infiltration in gingiva. Also, as recently reviewed by Buduneli 
and Scott, it has been found that smoking suppresses angiogenesis and this in 
turn leads to reduced inflammatory response [26, 309]. Further, a previous clinical 
study showed that smokers had a decreased blood vessel density and 
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inflammatory cells compared to nonsmokers although they have had an increased 
probing depth and overall increased clinical attachment loss [123]. This confirms 
the paradoxical action of smoking that it leads to reduced inflammation, however, 
apparent deleterious bone loss.  
 
The equivalent experiments in the acute model have not been completed due to 
the Covid-19 outbreak. 
 
A critical hall mark of periodontitis is alveolar bone resorption [44]. In both the 
chronic and acute models of periodontitis, smoke exposure significantly enhanced 
bacterial and/or ligature--induced alveolar bone loss. In the acute model, not only 
ligation enhances alveolar bone loss, but also infection and smoke exposure 
together had a synergistic effect on the alveolar bone. Successive representation 
of this aspect in-vivo is a reflective of a diagnostic key feature in periodontitis 
human smokers as confirmed by multiple studies [102, 310-312] and thus, in turn, 
validate these models as tools for study the association between P. gingivalis, 
smoking and periodontitis.  
 
In summary, reference cigarette smoke-exposure in a chronic model of 
periodontitis, altered aspects of systemic immune response to infection, 
augmented MMP-8 local expression and significantly enhanced bacterial-induced 
alveolar bone loss. While full analysis of the acute disease model was curtailed by 
the Covid-19 outbreak, smoke exposure clearly augmented alveolar bone loss. 
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Thus, both models reflect some, but not all, aspects of tobacco-enhanced 
periodontitis in humans. 
In the current study we presented two models of periodontitis. The acute model 
is less intensive and could be used to more rapidly screening for tobacco-
enhanced disease factors: e.g. P. gingivalis strains with mutants in tobacco-
essential genes; mice genetically manipulated in genes considered key to tobacco-
enhanced periodontitis. However, the chronic model, which better reflects the 
disease in humans, but is long-term and labor intensive, could subsequently be 
employed to examine relevant phenomena identified in the acute screening. 
These models could be improved by the following approaches: 
i) Polymicrobial infections: Periodontal diseases are multibacterial. This
model is amenable to both the minimalist approach presented herein as 
well as more complex infection protocols. IFurther, it has been 
previously shown that polymicrobial infection enhances colonization by 
P. gingivalis, T. denticola, and T. forsythia compared to their levels in 
monomicrobial infections [246]. 
ii) Wound healing: Incorporation of phase of ligature removal into the time
scheme of the acute model can be useful to assess the healing phase 
or to study the effect of anti-periodontitis medications [235]. 
iii) Optimize tobacco dosing: While our initial protocol was successful in
demonstrating tobacco-enhanced periodontal bone loss, it may be 
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possible to further exaggerate this phenomenon through optimizing 
exposure regimens. 
In conclusion, these models could be employed for: 
i) Study the association between gene mutations either in the pathogen or the
host and their relevance to periodontitis. For example, IL-10 knockout mice 
e hyperinflammation and are highly susceptible to P. gingivalis-induced 
periodontitis [286]. Also, clinical studies revealed that IL-10 gene 
polymorphism seems to be associated with severe chronic periodontitis 
[314]. 
ii) Alternate treatment regimens for smokers based on mechanistic insights
into smoke-enhanced bacterial induced periodontal diseases. For example, 
the Green tea catechin showed a bactericidal effect against Gram-negative 
rods and improved the periodontal status [315]. 
iii) Study tobacco-periodontitis-systemic disease exploitation. For instance,
utilizing these models to study periodontitis association with increased risk 
of cardiovascular diseases [316]. Also, the direct correlation between 
diabetes mellitus and periodontitis [317]. 
iv) Study tobacco-related microbial dysbiosis in a reproducible system.
Smoking showed a potential contribution in the alteration of microbial 
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equilibrium in subgingival tissues, thus worsening the severity of periodontal 
disease [226]. 
v) Adapt model to environmental tobacco smoke or passive smoking related
periodontal disease through use of side stream smoking machine [318]. 
vi) Adapt model to study marijuana-exacerbated disease: increasing evidence
suggests that inhalation of cannabis smoke is also negatively associated 
with periodontal health as recently reported [51]. 
vii) Evaluate the impact of smoking cessation to clinical and microbial variables
such as the bone loss and the bacterial colonization: studies show an early 
benefit of smoking cessation in terms of less reduction in pocket depth and 
gain in the level of clinical attachment in former smokers  compared to 
smokers [319].. 
viii) Delivery of electronic cigarettes aerosol through modified nebulizer to the
oral tissues to evaluate the effect of e-cigarettes in the current models [320]. 
Previous studies have shown the deleterious effects of e-cigarettes. For 
instance, E-cig containing nicotine affects oral myofibroblast differentiation 
in e-cig users; and hence may affect their ability to heal wounds by 
decreasing wound contraction by myofibroblasts[321]. Reactive 
aldehydes/carbonyls derived from e-cig aerosol can cause protein 
carbonylation and DNA adducts/damage, and carbonyls are cleaved by 
aldehyde dehydrogenase (ALDH). Protein carbonylation leads to 
autoantibody production, which may lead to destruction of matrix and bone 
loss during periodontitis [321].……………………………………………
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